Actimed Therapeutics
Focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | £1.0m Valuation: £77.5m | Early VC | |
| Total Funding | 000k | ||
| GBP | 2018 | 2019 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 51 % | - | (44 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (92 %) | (153 %) | (69 %) | (576 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (33 %) | (144 %) | (48 %) | (448 %) | (928 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 97 % | - | - | - |
Source: Company filings or news article
Related Content
Actimed Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for cachexia, a debilitating wasting disease associated with cancer and other serious chronic illnesses. The company aims to transform care for this underserved and vulnerable patient population by prolonging and improving their quality of life, restoring their dignity, and easing the burden for patients, carers, and healthcare providers. Actimed Therapeutics operates in the global biopharmaceutical market, focusing on research and development to bring new therapeutic options to market. The business model is centered around advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems worldwide. Revenue is generated through the development and commercialization of pharmaceutical products designed to treat cachexia. The company serves patients suffering from cancer-related cachexia and other chronic illnesses, healthcare providers, and caregivers.
Keywords: cachexia, biopharmaceutical, cancer, chronic illness, innovation, quality of life, clinical development, regulatory approval, healthcare, therapeutic.